Company research
Loading SEC business and financials…
AI relationship research has not yet been verified for this company.
Listing data synced 2026-09-10.
Loading your outlook…
Loading…
Loading company activity...
Estimated market cap
Unavailable
A supported share count and cached closing price are required.
Annual report for the year ended 2025-12-31. These are reported annual figures, not trailing twelve-month estimates.
We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. We intend to leverage our competencies and resources to positively impact human health. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies to generate a broad pipeline, including multiple commercial products and multiple programs in late-stage clinical development.
Excerpt from Item 1 — Business; filed 2026-02-26. May be shortened.
Source: SEC Company Facts. Checked 2026-09-30. Data is refreshed in the background. Missing or ambiguous figures are left unavailable.
Showing a previously fetched snapshot. A recent refresh has not completed.
